Azienda Unita Sanitaria Locale Di Modena
- Address
- lock Available on a paid plan
Neoplasms and Oncology Research
At Azienda Unita Sanitaria Locale Di Modena, the clinical trial portfolio in neoplasms focuses on several cancers, including breast cancer, prostate cancer, urothelial carcinoma, ovarian cancer, and small cell lung cancer. The studies are designed to test new treatment strategies, compare therapies, and improve outcomes for patients with advanced or high-risk disease.
- Testing targeted and endocrine-based approaches for early and high-risk breast cancer
- Evaluating treatment options for metastatic castration-resistant prostate cancer
- Assessing new combinations for bladder cancer and other urothelial cancers
- Exploring maintenance and supportive strategies in ovarian and lung cancer
These trials reflect a strong interest in improving cancer control through more personalized and effective therapies, with research supported by the hospital’s specialized gastrointestinal and endoscopic clinical environment.
Female Urogenital Diseases and Pregnancy Complications
Research in female urogenital diseases at this site includes studies on premature rupture of membranes during pregnancy, alongside cancer-related investigations affecting women, such as breast cancer and ovarian cancer. The main goal is to improve maternal and newborn outcomes while also refining treatment choices for women with complex oncologic conditions.
- Studying active management for pregnant patients with PROM
- Evaluating care strategies to reduce newborn respiratory support needs
- Supporting women with high-risk breast cancer through personalized treatment research
This mix of obstetric and oncologic research shows a broad commitment to women’s health, combining better diagnosis, treatment selection, and outcome improvement.
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The site also conducts studies in investigative techniques and clinical decision support, including research on colonoscopy preparation and biomarker-guided treatment planning. These trials aim to make diagnostic procedures more effective and to help clinicians choose treatments more precisely.
- Comparing bowel cleansing options for elective colonoscopy
- Using gene-expression tools to guide adjuvant therapy decisions in breast cancer
- Assessing biomarkers that may predict response to platinum-based chemotherapy
At UO Gastroentrologia ed Endoscopia Digestiva, this line of research supports better procedure quality, more tailored care, and improved use of diagnostic information in everyday practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Sanitaria Locale Di Modena
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa | GBG Forschungs GmbH | Phase II | Recruiting | Dec 2022 | — |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 4 | Unknown | 2018-07-31 | 2024-12-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.